Centro de Pesquisa em Cardiologia

Hospital das Clinicas da Universidade Federal de Goias

Acute Coronary Syndrome

Syndrome

Milvexian

Janssen (J&J Innovative Medicine)

condition

allSponsorName

Bristol-Myers Squibb (BMS)

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

Hospital das Clinicas da Universidade Federal de Goias | Centro de Pesquisa em Cardiologia

Site insights

Work at this site?

Active trials

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

Trial sponsors